




Avis pour l'opérationnalisation de la Stratégie de vaccination COVID-19 pour la Belgique

Advies voor de operationalisering van de vaccinatiestrategie COVID-19 voor België


Taskforce Operationalisering van de vaccinatiestrategie
Taskforce opérationnalisation de la Stratégie de vaccination

08/01/2021




Overview

COVID-19 VACCINE DEVELOPMENT, EVALUATION, APPROVAL AND MONITORING





Approval steps:



Who is involved:

Vaccine developers Submit the results of all testing to the medicines regulatory authorities in Europe

EMA scientific experts (CHMP, PRAC) Carry out scientific evaluation of vaccines

EMA pandemic Task Force (COVID-ETF) Enables EU Member States and the European Commission to take quick and coordinated regulatory action on the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19

European Commission Reviews EMA's scientific opinion and grants an EU-wide marketing authorisation in case of a positive outcome

National authorities Decide on introduction of the newly approved vaccine and vaccination policies




	Pfizer/BioNTech COMIRNATY®	Moderna	AstraZeneca	Janssen (Johnson & Johnson)	Curevac
Plateforme	mRNA BNT162b2	mRNA mRNA-1273	Non-replicating viral vector chimpanzee adenovirus vector (ChAdOx1)	Non-replicating viral vector adenovirus serotype 26	mRNA CVnCoV
Doses	2	2	2	1 ou 2	2
Efficacité	95,0%	94,1%	70,4% ¹	TBD	TBD
EMA Rolling review	06/10/2020	16/11/2020	01/10/2020	01/12/2020	-
EMA opinion	21/12/2020	06/01/2021	TBD	TBD	TBD
Commission Européenne (AMM)	21/12/2020	06/01/2021	TBD	TBD	TBD
Quantité de vaccins commandées ²	5 millions	2 millions	7,5 millions	5 millions	5 millions

TBD (To be determined), ¹Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (Updated 6 January 2021), ²https://www.afmps.be/fr/humain/medicaments/medicaments/covid_19/vaccins



Opérationnalisation de la stratégie vaccination – vue d’ensemble



Un plan par phases, conforme à la stratégie de vaccination

								
	Sous-segmentations possibles en fonction des capacités disponibles							
	Résidents et personnel maisons de repos et de soins ~290 K	Professionnels des soins de santé hôpitaux ~134 K	Professionnels des soins de santé 1 ^{ère} ligne ~156 K	Institutions collectives de soins et autre personnel hôpitaux ~300 K	65+ ambulants ~2 M	Patients à risque (comorbidités) ~1,3 M	Fonctions sociales et/ou économiques essentielles A définir	Population générale (18+) ~9,2 M
Mois début vaccination 	JAN	FIN JAN	FEV	FEV	MAR	MAR	AVR	JUIN
Vaccins disponibles 	Pfizer	Pfizer Moderna	Pfizer AstraZeneca Moderna	Pfizer AstraZeneca Moderna	Pfizer AstraZeneca Moderna	Pfizer AstraZeneca Moderna	Pfizer AstraZeneca Moderna J&J	Pfizer AstraZeneca Moderna Curevac J&J
Lieux de vaccination 	MRS	Hôpitaux	Hôpitaux + centres de vaccination	Hôpitaux et autres institutions	Centres de vaccination	Centres de vaccination	Centres de vaccination / médecine du travail	Centres de vaccination / médecine du travail


Projection théorique, sous réserve des approbations et livraisons

Le type de vaccin administré à chaque groupe sera défini en fonction de ses caractéristiques techniques et des lieux de vaccination




Impact adaptation calendrier vaccination (simulations)


Stratégie initiale
Proposition stratégie revue




Centres de vaccination: blueprint et simulations



Projet Anvers



Centres de vaccination: blueprint et simulations





Lignes directrices projet Heyssel



Centres de vaccination: blueprint et simulations

Optimal plan to optimize vaccine inventory levels and delivery
(end date of Vx campaign) is to build 200 Vx Centra by end March 2021




1 As per order book
2 Average vaccinations per month (vs. centres blueprint built for peak capacity)
Source: Order book as shared by AFMPS, Commissariat analysis

Centres de vaccination: blueprint et simulations

**View over time: Optimal plan to optimize vaccine inventory levels and delivery
(end date of Vx campaign) is to build 200 Vx Centra by end March 2021**

No of people that could be fully vaccinated, based on 100% delivery (as per contracted information and expected authorization of vaccines)



— 100 CENTERS
— 200 CENTERS
— 300 CENTERS



Frequently asked questions

Impact of vaccination on transmission

- No published or publically available data
- Is being looked at by vaccine manufacturers
- So far we cannot conclude or exclude that Pfizer or Moderna vaccine have impact on transmission

Data in children, pregnant women

- No data available – studies are planned in pregnant women and <16 y. population for Pfizer vaccine



Frequently asked questions

Delayed second dose

- in some countries = one of the alternatives to fasten the administration of the first dose to as many people as possible (in view of the variant in UK and SA)
- UK (up to 12 weeks), US (up to 42 days), WHO SAGE (up to 42 days in some circumstances), under review in Denmark and Germany, UK, in Canadian provinces, ...
- Worth to collect the scientific evidence (might offer a stronger booster response)
 - from vaccine trials to be set up (UK, KCE(?), contacts within EU)
 - from vaccine manufacturers?
 - Surveillance in UK and Canada (breakthrough infections after first dose)

Use of half doses

- US is studying the use of half a vaccine dose of mRNA as an alternative to administer a first dose to as many people as possible



Frequently asked questions

- Delayed second dose
- Use of half doses
- Intradermal administration
- ...

All very important and interesting from a scientific and public health point of view. Dose sparing alternatives in times of pandemic need to be looked at!

Plans remain unchanged in Belgium.



Frequently asked questions

Vaccination of COVID-19 positive subjects:

- Would require testing before vaccination
- Natural infection does not offer necessarily long term protection – cases of re-infection
- COVID-19 positive subjects included in the Pfizer and Moderna phase 3 vaccine trial:
 - Similar safety profile as COVID-19 negative subjects



Avis pour l'opérationnalisation de la Stratégie de vaccination COVID-19 pour la Belgique



Taskforce opérationnalisation de la Stratégie de vaccination

VERSION DU 02 DÉCEMBRE 2020

